2010/06/05

LAFEROBIONUM suppositoria rectalis

Pharmacological properties: interferon alfa-2b recombinant virus is expressed, antiproliferative and immunomodulating properties. The complex composition Laferobiona makes a number of new effects: in combination with tocopherol acetate and ascorbic acid, antiviral activity of interferon alpha-2b recombinant rises in 10-14, increased its immunomodulatory effects on T-and B-lymphocytes, normal maintenance of immunoglobulin E. There are no side effects (fever, chills, flu-like phenomena) arising from the parenteral administration of drugs interferon, does not generate antibodies that neutralize the antiviral activity of interferon alpha-2b recombinant interferon, even when using for the past 2 years, normal functioning of the endogenous system.

INDICATIONS: the drug is used in the treatment of various infectious and inflammatory diseases of children, including newborns and premature: at ARI, pneumonia (bacterial, viral, chlamydial etiology), meningitis, sepsis, specific intrauterine infection (chlamydia, herpes, cytomegalovirus, enterovirus infection , visceral candidiasis, mycoplasmosis) for the treatment of infections caused by Epstein - Barr virus in children.

APPLICATION: used rectally. The comprehensive treatment of various infectious and inflammatory diseases in children, including newborns and premature, a drug prescribed for the ME 150 000 to 2 suppositories per day with 12-hour break. Rates of treatment and the intervals between courses - 5 days. Recommended number of courses: at ARI - 1, of pneumonia of bacterial etiology - 1-2, viral etiology - 1, Chlamydia - 1, meningitis - 1-2, sepsis - 2-3, with specific fetal infections: HSV - 2, cytomegalovirus - 2 -3, enterovirus - 1-2, mycoplasmosis - 2-3.
Preterm newborns with gestational age ≤ 34 weeks of drug appoint 150 000 ME (a suppository) 3 times a day (after 8 h). The treatment course is 5 days.
In the treatment of infections caused by Epstein - Barr virus in children prescribed the drug at the rate of 1 million ME per 1 m 2 n the horse body weight per day. Recommended daily doses in children are: under 1 year - 250 000 ME; from 1 to 3 years - 500 000 ME; from 3 to 10 years - 500 000 - 1000000 ME; from 10 to 15 years - 1-1 , 5000000 ME; over 15 years - 1.5 million ME.
The drug is used 2 times a day with an interval of 12 h. The course of treatment is 10 days. If necessary, may conduct re-treatment after 5 days after the end of the first.

CONTRAINDICATIONS: Hypersensitivity to recombinant interferon alfa-2b or other component of the drug, thyroid disease, severe renal dysfunction, liver, severe cardiovascular disease, epilepsy and other diseases of the central nervous system (including functional) inhibition of the germ myeloid hematopoiesis.

SIDE EFFECTS: all adverse reactions associated with the use Laferobiona, minor or moderate severity. After treatment, they usually disappear.
With the introduction Laferobiona possible flu-like symptoms: chills, fever, fatigue, lethargy, and headache, myalgia, arthralgia, sweating). To reduce the severity of influenza-like symptoms recommended the appointment of paracetamol.
On the part of the hemopoietic system: long-term use may leukopenia, thrombocytopenia, anemia.
On the part of the gastrointestinal tract, liver: a higher level of ALT and AST, alkaline phosphatase in serum.
From the side of the central nervous system: long-term use may be dizziness, sleep disturbance.
Since the cardiovascular system: hypertension or hypotension, rarely - tachycardia.
Dermatological reactions: Long hair loss may be applied, which is restored after cessation of treatment.
It is also possible allergic reactions.

Cautions: The treatment Laferobionom should be under medical supervision. Prolonged use of the drug shall control the general analysis of blood, the functional parameters of liver, kidney and thyroid gland.
After the expiration date of drug use is unacceptable. The drug is not subject to perekontrolyu quality and prolong shelf life after it.